Objective-Stroke is a heterogeneous disease with diverse causes, which affect the risk of recurrence. This study aimed to identify novel biomarkers that are clinically relevant to the diagnosis of cardioembolic stroke (CE) and the prediction of stroke recurrence using metabolomics. Approach and Results-We obtained blood samples and clinical data from a consecutively registered, hospital-based acute stroke registry and from healthy controls. Mass-spectrometry-based profiling was performed, and several metabolomic signatures were selected for the discrimination of CE and stroke recurrence, coupled with multivariate statistical analysis. Finally, 190 acute ischemic stroke participants (43 CE patients and 147 non-CE patients) and 30 control participants were included. We obtained 29 metabolomics signatures, and of these, 2 medium-chain acylcarnitines (decanoylcarnitine and octanoylcarnitine) were selected as independent discriminants for CE (odds ratio, 2.839; 95% CI, 1.241-6.493 for decanoylcarnitine; odds ratio, 2.839; 95% CI, 1.241-6.493 for octanoylcarnitine). Elevated medium-chain acylcarnitines were also associated with a higher risk of stroke recurrence (hazard ratio, 3.767; 95% CI, 1.276-11.117 for decanoylcarnitine; hazard ratio, 5.519; 95% CI, 1.22-18.781 for octanoylcarnitine). The levels of decanoylcarnitine and octanoylcarnitine were correlated as known surrogate markers of CE. The levels of decanoylcarnitine and octanoylcarnitine were significantly higher in stroke patients with a high-risk potential of cardioembolism than in those with low or intermediate risk.
S
troke, a worldwide leading cause of mortality and disability, is a heterogeneous disease with various causes. 1 Cardioembolism is one of the main causes of stroke and is characterized by severe neurological deficits, a high recurrence rate, and different preventive regimens. 2 Diagnosis of cardioembolism solely depends on the identification of a high-risk potential source of cardioembolism (PSCE). Until recently, the modern diagnostic approach has used appropriate diagnostic tests to discriminate between stroke causes, and the proportion of cryptogenic stroke has diminished. However, a considerable proportion of stroke cause is still recorded as cryptogenic stroke. 3 For example, although paroxysmal atrial fibrillation has gradually been found using long-term ECG monitoring, 4 the proportion of cryptogenic stroke is still as high as 25%, even after vigorous investigation. 5 Consequently, the identification of novel biomarkers is another method through which to diagnose the cardioembolic sources.
Prediction of stroke recurrence is an additional major target of biomarker studies. In cardioembolic stroke (CE), in line with emerging novel oral anticoagulants, the proportion of patients that are appropriately treated with anticoagulants is increasing, and the risk of hemorrhagic complication is decreasing. 6 However, the recurrence rate of ischemic events in patients with CE, who are properly treated using oral anticoagulants, is as high as 0.9 to 1.7%, even when patients are closely monitored in a clinical trial setting. [7] [8] [9] [10] Furthermore, various circumstances inhibit the use of oral anticoagulants, which expose patients to elevated risk of ischemic events, 11 and the rate of stroke recurrence among patients with cardioembolism is ≈4.0% per year in real-world hospital-based stroke registry data. 12 The recurrence rate of CE has been reported as being higher than that of other stroke causes. Thus, it may be hypothesized that, if identified, biomarkers associated with cardioembolism could be predictive of stroke recurrence in cases of acute stroke.
Metabolomics offers new opportunities for the understanding of natural processes using the comprehensive detection and quantification of metabolites in biological systems. 13 As such, we can potentially identify changes in the levels of metabolites among acute stroke patients using metabolomics. Therefore, in the present study, we aimed to identify novel biomarkers for the discrimination of cardioembolism in patients with acute ischemic stroke using metabolomics. We further investigated whether these biomarkers offer predictive power for stroke recurrence prediction, supposing that the markers can exhibit a link to high recurrence rates in stroke patients.
Materials and Methods
The data that support the findings of this study are available from the corresponding author on reasonable request.
Study Design
This investigation, identified as MISS (Metabolomics in Ischemic Stroke Study), is a project that aims to investigate diagnosis, pathophysiological understanding, and outcome prediction in ischemic stroke using metabolomics. One of the main perspectives of the MISS project is to investigate differences in stroke subtypes, with an emphasis on CE in terms of potential mechanisms. The study protocol was approved by the institutional review board (KUGH 14179/ KUGH 11236) and written informed consent was obtained from each participant. Blood samples for metabolomics analyses were obtained from the Biobank of Korea University Guro Hospital, a member of the National Biobank of Korea.
Participants
Participants were recruited consecutively among acute stroke patients who registered at the Korea University Stroke Registry-Guro Arm between January 2014 and June 2016. Korea University Stroke Registry-Guro Arm is a part of a multicenter prospective hospitalbased stroke registry. It has identified demographic data, vascular risk factors, causative classification of stroke cases, neuroimaging findings, and clinical and neurological outcomes; details of this registry have been described elsewhere.
14 Eligibility criteria for study inclusion were that patients had an acute ischemic stroke within 7 days of sampling and the voluntary donation of blood samples. The diagnosis of ischemic stroke was based on the presentation of a relevant lesion through brain imaging, including diffusion-weighted imaging. The criteria for study exclusion included (1) a transient ischemic attack without a relevant lesion on diffusion-weighted imaging, (2) other determined cause or undetermined cause in the TOAST (Trial of Org 10 172 in Acute Stroke Treatment) classification (1), and (3) administration of lipid-lowering medications, such as statins, omega 3 supplementation, or fibrillation. As a control group, we also obtained blood samples, accompanied with medical histories, from vascular disease-free (no history of stroke, coronary artery disease, or peripheral artery disease) healthy controls from the same biobank resource. Stroke participants were classified, using the TOAST classification, into 5 categories. The detailed criteria were referenced by causative classification of stroke subtypes, and the risk of cardioembolism was estimated using the list of cardioaortic sources of cerebral embolism. 15 In this study, only 3 subtypes of stroke (large artery atherosclerosis, cardioembolism, and small vessel occlusion) were included to maximize the potential differences in metabolite expression. Furthermore, because the primary purpose of this study was to identify distinguishing features of CE, the stroke patient group was further classified into CE and non-CE.
Assessment of Clinical Outcomes
Participants that are registered in the Korea University Stroke Registry-Guro Arm are under investigation for recurrent vascular events, including any stroke, ischemic stroke, hemorrhagic stroke, as well as mortality at regular intervals, determined by the onset of the stroke. Data of the events were collected at discharge, 3 months after the event, and every year that followed. The informants were the participants or care-givers. If the participants were unable to visit the outpatient clinic, telephone interviews were performed by a trained coordinator. In this study, the rates of death (2 participants) and hemorrhagic stroke (3 participants) were low. We applied stroke recurrence as a primary outcome event.
Metabolomic Analyses
The detailed methods for metabolomic analyses are included in the online-only Data Supplement. In brief, blood samples were collected after at least 8 hours of fasting within 24 hours of arrival at the hospital. After preparing the samples using the traditional chloroform/ methanol method, we conducted liquid chromatography-mass spectroscopic analysis for polar and nonpolar metabolites using an Ultra Performance Liquid Chromatography system (UPLC-LTQ-Orbitrap XL, Thermo Fisher Scientific, MA) for nontargeted identification. We then identified the metabolites using METLIN, Human Metabolome DataBase, Lipid MAPS, MassBank, and Kyoto Encyclopedia of Genes and Genomes. In addition, the tandem mass spectrometry (MS/MS) spectra of metabolites were conducted using MS Frontier software to confirm the identification of metabolites.
Statistical Analyses
All values are presented as numbers (%) for categorical variables or mean±SD. Between-group comparisons were performed using the χ 2 test for categorical variables or the t test/Wilcoxon Rank-sum test for continuous variables, according to the distributions. Several factors, including decanoylcarnitine, octanoylcarnitine, and troponin I levels, were log-transformed because these variables were not normally distributed.
Because the primary objective of this study was to investigate the biomarkers associated with CE, we adopted several strategies to select candidate metabolites. For the assessment of the effect of each metabolite on the specific groups, fold changes, P values (Wilcoxon Ranksum test), and false discovery rate-adjusted P values are presented for each metabolite. Global discrimination between the metabolomics data from each group was then performed using the partial least squares-discriminant analysis (PLS-DA) scores, which were generated using SIMCA-P+ software 14.1 (Umetrics, Umea, Sweden on the PLS weights, and the variability was explained in PLS-DA. We also conducted a random forest model analysis to discriminate between the CE and non-CE groups. For the random forest model analysis, randomForest packages were used (https://cran.r-project. org/web/packages/randomForest/index.html). Finally, we used univariate logistic regression analysis and metabolites with significant association with CE were selected. To obtain the independent association of CE and participants' characteristics, univariate and multivariate logistic regression analyses were used. At first, we attempted to select candidate metabolites using the variable importance for the projection score from the PLS-DA or random forest models. However, because the discriminating power of the PLS-DA and random forest models were not satisfactory, we used the metabolites which had a significant association in univariate logistic regression analyses as candidate metabolites. The rank for main metabolites obtained from fold changes, random forest analysis, and PLS-DA was also provided.
To reveal the association between each metabolite and recurrent stroke, univariate Cox regression analyses were performed. To show the independent association of metabolites with recurrent stroke, 2 multivariate Cox regression analyses were performed: in model 1, the CHA 2 DS 2 -VASc score was included as a covariate, whereas in model 2, the variables that were proven to be associated with recurrent stroke in univariate models were included. The cumulative hazard ratio (HR) and cubic spline plots were used to display the effect of the metabolites that were selected as markers for cardioembolism in this study on stroke recurrence.
The association of the important metabolites and the features obtained from clinical and laboratory information is illustrated as a correlogram.
Statistical analyses were conducted using the R language version 3.4.4 (R Foundation for statistical computing, Vienna, Austria), except for global discrimination analyses for the MS data. P values < 0.05 were considered to be statistically significant.
Results

Participants
Among the 810 participants that were registered with the Korea University Stroke Registry-Guro Arm during the study period, a data set of 190 participants with stroke (67.9% male; age, 67.5±12.5 years old) was analyzed in this study ( Figure 1 ; Table I in the online-only Data Supplement). The stroke group was composed of 147 non-CE (77.4%) and 43 CE (20.2%) cases. Of the patients with CE, 39 participants had a high-risk PSCE, whereas 8 participants had low or uncertain risk PSCE (4 participants had 2 PSCEs). There were statistically significant differences in age, diabetes mellitus, smoking status, atrial fibrillation, blood urea nitrogen, creatinine, free fatty acid (FFA), hemoglobin A1c, uric acid, and fibrinogen between the CE and non-CE groups (Table 1) . Multivariate logistic regression analysis incorporating these covariates (other than atrial fibrillation, FFA, and the National Institute of Health Stroke Scale value) revealed that age, diabetes mellitus, total cholesterol, uric acid, and fibrinogen were independently associated with CE (Table II in 
Discrimination Between Stroke Cases and Controls Using Metabolomics Data
Untargeted metabolomics data recorded aligned metabolic features for each serum sample in MS positive ion mode. After re-evaluation of the features, 29 metabolites were identified by mass chromatographic testing, including 14 polar metabolites and 15 nonpolar metabolites (Table III in the online-only Data Supplement). Among these metabolites, 16 metabolites showed a significant association with the stroke group, with the highest fold changes in phosphonic acid, Gly-l-Val, and glutamine (Tables II and III in the online-only Data Supplement). The stroke group was distinguished from controls with modest discriminatory power using PLS-DA (Q value 44.0%; Figure IA in the online-only Data Supplement). The variable importance for the projection value was the highest for Gly-l-Val, followed by arginine, phosphonic acid, ceremide, octanoylcarnitine, and decanoylcarnitine ( Figure IC 
Selecting a Candidate Biomarker for the Discrimination Between CE and Non-CE
Through univariate logistic regression analysis, 5 metabolites showed significant association with CE group, with the highest odds ratio in glutamine, decanoylcarnitine, octanoylcarnitine, phenylalanine, and aspartame acid ( Table 2; Table  V in the online-only Data Supplement). In fold change analysis, there was a significant difference in the level of 5 metabolites between the CE and the non-CE groups, with the highest fold changes in glutamine, decanoylcarnitine, octanoylcarnitine, lysophosphatidylcholine (18:0), lysophosphatidylcholine (16:0), and phosphatidylcholine (38:7; Figure 2 ). Discrimination between the CE and non-CE groups through PLS-DA (Q 2 value 3.4%) and the random forest model (out-of-bag error rate 23.94%) showed unsatisfactory discriminating power (Figures III and IV in the online-only Data Supplement). The summary of the results of these analyses is presented in Table III in the online-only Data Supplement. Finally, we selected decanoylcarnitine and octanoylcarnitine as the candidate biomarkers as they showed an association with the CE group in all of the models that were performed. Multivariate logistic regression analysis, with adjusted clinical covariables, confirmed that decanoylcarnitine (odds ratio, 2.839; 95% CI, 1.241-6.493) and octanoylcarnitine (odds ratio, 2.839; 95% CI, 1.241-6.493) were independently associated with CE ( Table 2) .
Correlation of Decanoylcarnitine and Octanoylcarnitine With the Clinical and Laboratory Parameters that Are Associated With CE
Among the vascular risk factors, older age (P=0.001 for decanoylcarnitine; P=0.008 for octanoylcarnitine) and atrial fibrillation (P=0.001 for both decanoylcarnitine and octanoylcarnitine) were associated with higher decanoylcarnitine and octanoylcarnitine levels (Table VI in the online-only Data Supplement). Male sex (P=0.039) and hypertension (P=0.040) were associated only with higher decanoylcarnitine levels. The levels of decanoylcarnitine and octanoylcarnitine were significantly higher in stroke patients with high-risk PSCE than those with low-or intermediate-risk PSCE (P=0.040 for decanoylcarnitine, P=0.044 for octanoylcarnitine) and those without PSCE (P<0.001 for both decanoylcarnitine and octanoylcarnitine; Figure 3 ). Figure 4 displays the correlation between both decanoylcarnitine and octanoylcarnitine with the clinical and laboratory factors. Both of these metabolites showed significant positive correlations with FFA, troponin I, lipoprotein a, uric acid, fibrinogen, homocysteine, NT-proBNP (N-terminal pro-B-type natriuretic peptide), National Institute of Health Stroke Scale, CHADS 2 , and HAS-BLED scores. In addition, decanoylcarnitine was positively correlated with high sensitivity-CRP (C-reactive protein) and negatively correlated with HDL (high-density lipoprotein)-cholesterol.
Predictive Power of Decanoylcarnitine and Octanoylcarnitine for Stroke Recurrence
The mean follow-up duration for the participants with stroke was 15.9 months (median, 15.8 months; interquartile range, 4.8-20.7 months). Thirteen participants (6.8%) were lost from follow-up after discharge. Among the 190 participants, ischemic stroke, hemorrhagic stroke, unknown stroke, and death were observed in 15, 3, 2, and 2 participants, respectively. Among those with any form of stroke, 1 participant had both ischemic and hemorrhagic strokes. Univariate Cox regression analysis revealed that stroke recurrence was associated with age (P=0.006), low stature (P=0.025), D-dimer levels (P=0.040), troponin I concentration (P=0.006), and National Institute of Health Stroke Scale (P=0.021; with missing values were deleted (n=6), the statistical significance of decanoylcarnitine (P=0.022) and octanoylcarnitine (P=0.010) was maintained. When cubic spine plot regression was used to explore the adjusted association between decanoylcarnitine and octanoylcarnitine and stroke recurrence, we observed an approximately log-linear increase in the hazard of stroke recurrence as the proportions of octanoylcarnitine and decanoylcarnitine increased ( Figure 5 ). The difference in the cumulative HR for stroke recurrence between the groups with the higher and lower levels of decanoylcarnitine and octanoylcarnitine steadily increased from study entry to the cessation of follow-up. None of the other metabolites that were identified by metabolomic analyses exhibited a significant association with stroke recurrence (Table 3; Table VIII in the online-only Data Supplement).
Discussion
The purpose of this study was to identify novel biomarkers that could be used to discriminate CE and predict stroke recurrence using metabolomics. We found that decanoylcarnitine and octanoylcarnitine were verified as independent factors for determining CE. These metabolites were also found to be associated with an increased risk of stroke recurrence (central illustration).
The diagnosis of stroke subtype is still a challenge for stroke physicians. Many researchers have sought to identify candidate biomarkers that are linked to CE. 16 The majority of biomarker candidates are presumed to play a pathophysiological role in CE occurrence and, therefore, researchers usually search for biomarkers among those that have known ). FDR-P indicates false discovery rate-adjusted P value.
pathophysiological links with CE, including inflammation, hypercoagulability, or endothelial damage. 17 However, different stroke causes usually share major common pathogenic mechanisms and, therefore, most biomarkers that are identified through these methods are not specific for CE but are rather biomarkers for generalized stroke causes, or in some cases, other vascular diseases. Hence, caution is warranted in using these nonspecific biomarkers in clinical practice. 16 For example, the blood biomarkers that exhibit the highest sensitivity and specificity for CE, such as brain natriuretic peptide, D-dimer, or creatinine kinase muscle-brain, are not specific markers for CE, but rather, indicators of cardiac diseases. 16 In this context, a strength of the present study is the use of untargeted metabolomics, in which there is no intent to search for specific mechanism-oriented markers. Untargeted metabolomics has a global scope without hypothesis. 18 This unbiased approach quantitates as many metabolites as possible and compares these measurements between samples. There is a great potential for the use of this approach to provide insights into fundamental biological processes. 18 Until now, few studies have used metabolomics to investigate stroke pathophysiology. 19, 20 In a study performed on 28 acute stroke patients with small vessel occlusion and 30 healthy controls, distinctive metabolite features were found, which were associated with anaerobic glycolysis, folic acid deficiency, and hyper-homocysteinemia. 19 This study showed that energy metabolism was a distinctive feature in stroke participants. A comparison between 40 acute ischemic stroke patients and 29 matched controls revealed that the levels of amino acid metabolites, such as tyrosine, lactate, and tryptophan, were different between the groups. 20 However, this finding did not investigate further to identify the different mechanisms involved in different subtypes of stroke. In contrast, in the present study, we identified 2 metabolites, which act on mitochondrial β-oxidation, that display an independent association with CE and stroke recurrence.
Two distinct mechanisms could be proposed to explain the observed correlation between acylcarnitines and CE. First, elevated acylcarnitines reflect accompanying cardiac diseases, which have the potential to produce cardioembolism. Mitochondria are essential for the maintenance of cardiac contractility through the continual and ongoing energy supply via ATP generation. 21 Second, mitochondrial fatty acid β-oxidation represents the most efficient and predominant substrate for energy production in the normal adult human heart. During mitochondrial β-oxidation, L-carnitine is one of the key metabolites that transports cytosolic fatty acids across the inner mitochondrial membrane, by forming acylcarnitines, resulting in esterification of L-carnitine to form acylcarnitines. 22 Therefore, elevated circulatory acylcarnitines may reflect dysregulation of mitochondrial β-oxidation and dysfunctional myocardial disease. Mitochondria are known to be associated with cardiovascular diseases because of their primary role is as the powerhouse of all cells, and cardiac myocytes are the main agents of energy consumption. 8 However, recent information has been accumulated on the complex interaction between mitochondria and the regulation of metabolism or cell death, with an emphasis on the role of mitochondria as potential therapeutic targets or as candidates for risk-predictive biomarkers. 21 Importantly, our observations add stroke to the list of acylcarnitine-associated vascular events, which seems to be a novel finding. In this study, the proportion of circulating acylcarnitines was found to be positively correlated with NT-proBNP and fibrinogen, which are well-known biomarkers of cardioembolism for those at high risk of PSCEs. [23] [24] [25] Furthermore, the proportion of acylcarnitines was higher in participants at high risk of PSCEs, which was not apparent for those at low or uncertain risk of PSCEs. Therefore, elevated circulating medium-chain acylcarnitines could reflect the presence of potential sources of cardioembolism. Second, elevated circulating acylcarnitines could be associated with thrombogenicity. A previous study, using animal models, revealed that fatty acid infusion to the circulation produced massive thrombosis. 26 Elevated fatty Phosphatidylethanolamine alkenyl −1.110 5
The metabolites were selected if they showed a significant FDR-P value in t tests, a higher VIP score in PLS-DA, or a significant association in univariate logistic regression analyses. Rank-1 is the rank of the mean decrease in accuracy obtained from the random forest model. Rank-2 is the rank of the mean decrease in GINI obtained from the random forest model. CE indicates cardioembolic stroke; FDR, false discovery rate; OR, odds ratio; PLS-DA, partial least square-discriminant analysis; and VIP, variable importance for the projection.
acid levels enhance thrombosis in conjunction with platelet activation, increase oxidative stress, and control fibrinogen biosynthesis. 27, 28 Supporting this FFA-thrombogenicity relationship, recent observations in ischemic stroke studies have revealed that elevated FFA can predict CE subtypes. [29] [30] [31] [32] [33] The present study can be interpreted in conjunction with these previous observations, about the link between elevated FFA and CE, because acylcarnitines are a key metabolite for FFA turnover. This possible association was reinforced by a positive correlation of acylcarnitines with FFA levels in this study. Adding acylcarnitines to the clinical model revealed the independent association between acylcarnitines and CE and stroke recurrence.
Another important finding of this study is that mediumchain acylcarnitines are also predictive for stroke recurrence. This relationship was not observed with the other measured metabolites and was independent of clinical factors. Currently, only one other study has reported predictors for stroke recurrence using metabolomics. 34 In patients with transient ischemic attacks, low concentrations of lysophosphatidylcholine (16:0) were associated with stroke recurrence. However, a direct comparison with the results presented in this study is not appropriate because the participants were substantially different. Among the lipid-metabolic markers for stroke recurrence, elevated FFA was presented as predictive for stroke recurrence among patients with CE. 12, 29 However, until recently, acylcarnitines have not been proposed as predictors for stroke recurrence. Unlike in stroke, elevated circulatory levels of acylcarnitines, measured using metabolomic techniques, reflect the risk of cardiovascular diseases or insulin resistance. [35] [36] [37] [38] It has previously been reported that the levels of acylcarnitines are elevated in coronary artery disease and are predictive of subsequent cardiovascular events. 37, 38 The prognostic power of acylcarnitine for cardiovascular diseases was independent of clinical factors, consistent across elderly participants and those under dialysis, and high-risk participants without cardiovascular disease. 35, 36, 39 In addition to the main results, this study offers another interesting observation: medium-chain acylcarnitines were elevated in patients with atrial fibrillation. At present, we are only able to speculate whether this association involves mitochondrial oxidative stress as one of the main mechanisms capable of resulting in atrial fibrillation.
The present study has several limitations. First, the participants in this study were all ethnically Korean. Although previous studies that were conducted in populations of non-Asian ancestry revealed a similar association between acylcarnitines and cardiovascular events, 35, [37] [38] [39] validation of these results in ethnically different populations is required. In addition, although this study was conducted in a consecutive manner, a significant proportion of the participants did not donate blood samples, which may have resulted in selection bias. Second, participants were included from a single referral center-based stroke registry. Multicenter-based validation is necessary before these findings can be generalized to a broader population. Third, we used nontargeted metabolomics analyses, and only 2 medium-chain acylcarnitines were detected. Targeted metabolomics analysis, to validate these results, are warranted. Fourth, LC-MS-based metabolite measurements may not necessarily have a direct clinical translation. However, LC-MS is considered the technique of choice for nontargeted global metabolite profiling efforts. 18 Fifth, although our data revealed an association between metabolic profiles and CE, the pathophysiological mechanisms remain unknown. Thus, to date, we have had no answer to the question of how we can apply the links between acylcarnitine and cardioembolism to clinical and therapeutic aspects. Sixth, this study enrolled acute stroke patients with evident causes. However, the biomarkers for stroke subtype are more useful for cryptogenic stroke. Therefore, future research should investigate cryptogenic stroke and attempt to settle the issue of validity for the assessment of cryptogenic stroke. Despite these limitations, this study has major strengths, including novel findings in a stroke cohort, retrospectively collected registry-based data, vigorous control of confounding factors, and the production of consistent, verified, and reproducible findings across various methods of analyses.
Conclusions
The results demonstrate that medium-chain acylcarnitines are positively associated with CE events and are significantly associated with stroke recurrence. These associations are independent and consistent. Further validation of the value of medium-chain acylcarnitines as novel biomarkers for CE and stroke recurrence should be performed.
